Niagen Bioscience (NAGE) Divestments (2013 - 2026)

Niagen Bioscience (NAGE) posted quarterly Divestments of $5.8 million for Q1 2026, up 215.1% quarter-over-quarter from $1.8 million in Q1 2015.

Niagen Bioscience (NAGE) Divestments (2013 - 2026) Analysis & Trends

Niagen Bioscience (NAGE) has reported Divestments for 3 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.

In Q1 2026, Divestments changed N/A year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $8.1 million (changed N/A YoY), while the FY2015 annual figure was $1.8 million, changed N/A from the prior year.
Divestments improved to $5.8 million in Q1 2026 per NAGE's latest filing, from $1.8 million in the prior quarter.
Across five years, Divestments topped out at $5.8 million in Q1 2026 and bottomed at $5.8 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	9.82 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-13.21 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Niagen Bioscience	238.30 Mn	171.56 Mn	19.31 Mn	-

Download Data